MARITIME-CV
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text css=""] Summary of a new Cardiovascular Outcomes Trial (CVOT) called "MARITIME-CV": This study is being done to learn more about maridebart cafraglutide (MariTide) in people with atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight in addition to their routine...

